Novo Nordisk Pharma - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 10,926,705 | 11,315,674 | 12,120,166 | 14,255,889 | 16,385,375 | 21,820,183 | 28,628,471 | 40,026,604 |
| Profit before tax | 413,954 | 309,066 | 326,763 | 377,747 | 637,785 | 912,567 | 1,223,040 | 1,604,359 |
| Net profit | 328,222 | 250,993 | 274,122 | 312,935 | 528,683 | 752,671 | 1,010,395 | 1,270,136 |
| Equity | 541,309 | 467,303 | 491,425 | 554,359 | 1,083,042 | 1,835,713 | 2,846,108 | 3,116,244 |
| Liabilities | 1,674,713 | 1,186,951 | 1,768,589 | 2,413,145 | - | 4,375,007 | 8,494,236 | 11,142,413 |
| Non-current assets | 19,481 | 18,629 | 24,619 | 22,068 | 32,825 | 35,460 | 66,940 | 63,693 |
| Current assets | 2,274,911 | 1,735,016 | 2,300,647 | 3,029,446 | 3,073,253 | 6,332,559 | 11,429,793 | 14,286,453 |
| Total assets | 2,294,392 | 1,753,645 | 2,325,266 | 3,051,514 | 3,106,078 | 6,368,019 | 11,496,733 | 14,350,146 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 1,556,910 | 2,084,480 | 2,699,920 |
| Social insurance contributions | - | - | - | - | - | 474,824 | 551,217 | 647,425 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -5.1% | +3.6% | +7.1% | +17.6% | +14.9% | +33.2% | +31.2% | +39.8% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 14.3% | 14.3% | 11.8% | 10.3% | 17.0% | 11.8% | 8.8% | 8.9% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 60.6% | 53.7% | 55.8% | 56.4% | 48.8% | 41.0% | 35.5% | 40.8% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 3.0% | 2.2% | 2.3% | 2.2% | 3.2% | 3.4% | 3.5% | 3.2% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 3.8% | 2.7% | 2.7% | 2.6% | 3.9% | 4.2% | 4.3% | 4.0% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 3.1 | 2.5 | 3.6 | 4.4 | - | 2.4 | 3.0 | 3.6 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 546,335 | 543,153 | 611,102 | 715,776 | 762,110 | 941,877 | 1,063,595 | 1,356,834 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Novo Nordisk Pharma - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-03-29 | 2026-03-31 | 35.08 |
| 2026-03-26 | 2026-03-26 | 35.08 |
| 2026-02-18 | 2026-03-09 | 2.59 |
| 2023-01-17 | 2023-01-18 | 13832.09 |
Novo Nordisk Pharma - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-04-10 | 2026-04-13 | 43.03 |
| 2026-04-01 | 2026-04-09 | 43.11 |
| 2026-03-29 | 2026-03-31 | 0.53 |
| 2026-03-19 | 2026-03-27 | 0.53 |
| 2026-02-28 | 2026-03-12 | 0.53 |
| 2026-02-21 | 2026-02-21 | 0.53 |
| 2026-01-29 | 2026-02-03 | 0.53 |
| 2026-01-01 | 2026-01-23 | 0.53 |
| 2025-11-28 | 2025-12-02 | 0.53 |
| 2025-09-28 | 2025-11-25 | 0.53 |
| 2025-09-19 | 2025-09-25 | 0.53 |
| 2025-08-28 | 2025-09-11 | 0.53 |
| 2025-07-28 | 2025-08-25 | 0.53 |
| 2025-06-28 | 2025-07-25 | 0.53 |
| 2025-06-19 | 2025-06-25 | 0.53 |
| 2025-05-29 | 2025-06-10 | 0.53 |
| 2025-04-28 | 2025-05-20 | 0.53 |
| 2025-03-28 | 2025-04-10 | 0.53 |
| 2025-03-26 | 2025-03-27 | 0.32 |
| 2025-03-20 | 2025-03-25 | 0.53 |
| 2025-03-19 | 2025-03-19 | 0.32 |
| 2025-03-15 | 2025-03-18 | 0.53 |
| 2025-02-28 | 2025-03-14 | 0.61 |
| 2025-02-26 | 2025-02-27 | 0.4 |
| 2025-02-21 | 2025-02-25 | 0.61 |
| 2025-02-20 | 2025-02-20 | 0.21 |
| 2025-01-30 | 2025-02-18 | 0.21 |
| 2024-12-30 | 2025-01-27 | 0.21 |
| 2024-12-19 | 2024-12-20 | 0.21 |
| 2024-11-28 | 2024-12-11 | 0.21 |
| 2024-10-28 | 2024-11-25 | 0.21 |
| 2024-09-29 | 2024-10-16 | 0.21 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Novo Nordisk Pharma, UAB (company code 300114028) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In the latest financial year, 2025, revenue reached €40.03M, up 39.8% year on year and 83.4% over two years. Net profit was €1.27M, compared with €1.01M in 2024 and €752.7K in 2023, showing steady earnings growth alongside expansion. Profit margin remained relatively stable at 3.2% in 2025, after 3.5% in 2024 and 3.4% in 2023. The balance sheet also expanded, with total assets increasing to €14.35M from €11.50M in 2024 and €6.37M in 2023. Equity rose to €3.12M, while liabilities increased to €11.14M, leaving the equity ratio at 21.7% and the debt-to-equity ratio at 3.58. Assets were concentrated in short-term items, and asset turnover stood at 2.79x. Profitability indicators were solid, with ROE at 40.8% and ROA at 8.8%. Revenue per employee was €1.38M, indicating high productivity.